Nasopharyngeal Cancer Treatment

Nasopharyngeal cancer (NPC) is a distinct malignancy arising from the epithelial lining of the nasopharynx -- the uppermost part of the throat, situated directly behind the nasal cavity and above the soft palate. Unlike other head and neck cancers, NPC has unique epidemiological, viral, and treatment characteristics that set it apart. At THANC Hospital in Chennai, Dr. Vidhyadharan Sivakumar, MCh (Head & Neck Surgery), FEB-ORL HNS, FICRS, provides comprehensive NPC management -- from initial diagnosis through chemoradiation to complex endoscopic salvage surgery for recurrent disease. His skull base surgery training at Toronto General Hospital, Canada, equips him with the specialized expertise required for the most challenging nasopharyngeal tumors.

Understanding Nasopharyngeal Cancer

The nasopharynx is a box-like chamber approximately 4 cm in each dimension, located at the junction of the nasal cavity and the upper throat. It houses the openings of the Eustachian tubes (connecting to the middle ear) and the adenoid tissue. Cancer in this region behaves differently from other throat cancers because of its deep anatomical location, proximity to the skull base, and strong association with Epstein-Barr virus (EBV).

NPC accounts for approximately 2% of all head and neck cancers globally, but its incidence varies dramatically by geography. While endemic in southern China and Southeast Asia (incidence rates of 20-30 per 100,000), India sees a lower but significant number of cases, particularly in the northeastern states of Nagaland, Mizoram, and Manipur, where incidence rates approach 5-8 per 100,000 -- several times higher than the Indian national average. Cases are also seen across Tamil Nadu and other southern states, often presenting at advanced stages due to the hidden location of the tumour and non-specific early symptoms.

Understanding the staging of head and neck cancers is essential for NPC patients, as the treatment approach and prognosis differ significantly between early-stage and advanced disease.

Types and Classification

The World Health Organization (WHO) classifies nasopharyngeal carcinoma into three histological types:

• Type I -- Keratinizing Squamous Cell Carcinoma: Resembles typical squamous cell carcinoma seen elsewhere in the head and neck. Less common in endemic areas, more frequently seen in older patients, and less strongly associated with EBV. Generally carries a poorer prognosis compared to other subtypes.

• Type II -- Non-Keratinizing Differentiated Carcinoma: Shows squamous differentiation but without keratin production. Strongly associated with EBV infection. More radiosensitive than Type I.

• Type III -- Non-Keratinizing Undifferentiated Carcinoma (formerly "Lymphoepithelioma"): The most common subtype in endemic regions, strongly EBV-associated, and paradoxically carries the best prognosis due to high sensitivity to radiation and chemotherapy. This subtype is also the most common type seen in Indian patients.

The distinction between these subtypes is clinically important because Type II and III tumours respond significantly better to chemoradiation than Type I, which influences treatment planning.

Causes and Risk Factors

NPC has a multifactorial etiology. The following risk factors are well established:

• Epstein-Barr Virus (EBV): EBV DNA is detected in virtually all non-keratinizing NPCs. The virus plays a direct role in tumour development by promoting cell proliferation and inhibiting apoptosis. EBV serology (VCA-IgA, EA-IgA) and plasma EBV DNA levels are used both for screening in high-risk populations and for monitoring treatment response.

• Dietary Factors: Consumption of salt-preserved fish, meats, and vegetables -- particularly during childhood -- is a well-documented risk factor. Nitrosamines and nitrosamine precursors in these preserved foods are believed to be carcinogenic. In India, consumption of smoked meats and fermented fish in the northeastern states correlates with the higher regional incidence.

• Tobacco and Alcohol: While tobacco is a dominant risk factor for most head and neck cancers, its role in NPC is more modest for the non-keratinizing subtypes. However, smoking increases the risk of keratinizing NPC. In India, both smoking and smokeless tobacco (gutka, pan masala) are relevant contributing factors.

• Genetic Susceptibility: Certain HLA haplotypes (HLA-A2, HLA-B46) are associated with increased NPC risk. Family clustering of NPC cases is well documented, particularly in endemic populations.

• Occupational Exposures: Exposure to formaldehyde, wood dust, and industrial fumes has been linked to increased NPC risk, relevant to workers in India's manufacturing and woodworking sectors.

• Poor Ventilation and Indoor Smoke: Exposure to wood-burning stove smoke and poor household ventilation, common in parts of rural India, is an emerging area of epidemiological interest.

India-Specific Epidemiology

India presents a unique NPC landscape. While the overall national incidence is low (0.5-1 per 100,000), the northeastern states have rates 5-10 times higher, attributed to dietary habits, genetic factors, and potentially environmental exposures. Cases in Tamil Nadu and the rest of southern India tend to present at more advanced stages (Stage III-IV), often because early symptoms are attributed to routine ENT conditions like sinusitis or middle ear infections. This pattern of late presentation underscores the need for increased awareness among both patients and primary care physicians.

Signs and Symptoms

NPC symptoms are often subtle and non-specific in the early stages, contributing to diagnostic delays. Key symptoms include:

• Neck lump: A painless, firm mass in the upper neck (often behind the angle of the jaw) is the most common presenting symptom, occurring in up to 70% of patients. Many patients are initially evaluated for a "neck lump" without suspecting the nasopharyngeal primary.

• Nasal symptoms: Unilateral nasal obstruction, blood-stained nasal discharge (epistaxis), and post-nasal drip.

• Ear symptoms: Unilateral serous otitis media (fluid in the middle ear) causing hearing loss, tinnitus, or a feeling of ear fullness. In any adult presenting with unilateral middle ear effusion, NPC must be excluded.

• Cranial nerve involvement: As the tumour extends toward the skull base, it can compress or infiltrate cranial nerves, causing double vision (diplopia), facial pain or numbness (trigeminal nerve), and facial weakness.

• Headache: Persistent, localised headache -- particularly in the occipital or temporal region -- may indicate skull base erosion.

• Trismus: Difficulty opening the mouth due to infiltration of the muscles of mastication.

Any adult presenting with unexplained unilateral ear symptoms, persistent nasal bleeding, or a neck mass should undergo thorough nasopharyngeal examination to rule out NPC.

Diagnosis at THANC Hospital

Dr. Vidhyadharan employs a systematic diagnostic protocol for suspected NPC:

• Flexible Nasoendoscopy: The cornerstone of diagnosis. A thin, flexible fibre-optic endoscope is passed through the nose to directly visualise the nasopharynx. Any suspicious lesion is biopsied. At THANC Hospital, high-definition nasoendoscopy with narrow-band imaging (NBI) enhances the detection of mucosal abnormalities that may be missed on standard endoscopy.

• Imaging:

  • MRI with contrast is the preferred imaging modality for NPC because it provides superior soft-tissue detail, accurately delineates tumour extent, skull base invasion, and intracranial extension.
  • CT scan complements MRI by providing detailed bone anatomy, particularly useful for assessing skull base erosion.
  • PET-CT is used for accurate staging, detecting distant metastases, and assessing treatment response.

• EBV Serology and Plasma EBV DNA: Elevated EBV-related antibodies (VCA-IgA, EA-IgA) and circulating EBV DNA levels support the diagnosis and serve as valuable biomarkers for monitoring treatment response and detecting recurrence.

• Biopsy and Histopathology: Endoscopic-guided biopsy of the nasopharyngeal lesion provides the definitive diagnosis. Immunohistochemistry for EBV (EBER in-situ hybridisation) is performed routinely.

• Audiological Assessment: Baseline hearing evaluation is important given the frequency of ear involvement and the potential ototoxicity of cisplatin-based chemotherapy.

Treatment Approach

Unlike most head and neck cancers where surgery is the primary treatment, NPC management follows a distinct paradigm due to the tumour's anatomical inaccessibility and exquisite radiosensitivity.

Primary Treatment: Concurrent Chemoradiation

The standard of care for Stage II-IVB NPC is concurrent chemoradiation therapy (CCRT):

• Intensity-Modulated Radiation Therapy (IMRT): IMRT is the radiation technique of choice, delivering precise radiation doses to the tumour while sparing surrounding structures -- particularly the parotid glands (to preserve saliva production), brainstem, optic pathways, and temporal lobes. Total dose is typically 70 Gy delivered over 7 weeks.

• Concurrent Cisplatin Chemotherapy: Weekly or three-weekly cisplatin is administered alongside radiation. The chemotherapy sensitises tumour cells to radiation, significantly improving cure rates compared to radiation alone.

• Induction Chemotherapy: For locally advanced disease (Stage III-IVB), induction chemotherapy with gemcitabine-cisplatin or docetaxel-cisplatin-5FU (TPF) before CCRT has shown improved outcomes in recent landmark trials.

For Stage I NPC, radiation alone (without chemotherapy) is often curative.

Surgical Salvage for Recurrent or Persistent Disease

Surgery enters the treatment algorithm when disease persists or recurs after primary chemoradiation. This is where Dr. Vidhyadharan's skull base surgery training at Toronto General Hospital, Canada, becomes particularly relevant. Salvage surgery for nasopharyngeal recurrence is among the most technically demanding procedures in head and neck surgical oncology.

Endoscopic Nasopharyngectomy: Dr. Vidhyadharan performs endoscopic nasopharyngectomy -- a minimally invasive approach that accesses the nasopharynx through the nasal passages using endoscopes and powered instruments, without any external incisions. This technique is suitable for recurrent tumours confined to the nasopharynx (rT1-rT3) and offers several advantages over open salvage approaches. Understanding the role of skull base surgery in managing these complex tumours provides important context for patients facing recurrent NPC.

Treatment Comparison Table

How Dr. Vidhyadharan Manages NPC

Dr. Vidhyadharan's approach to NPC management is shaped by his training across multiple international centres. His skull base surgery training at Toronto General Hospital (University of Toronto), Canada -- one of the world's leading centres for endoscopic skull base surgery -- provided specialised expertise in endonasal approaches to the nasopharynx, clivus, and parasellar regions. This training is directly applicable to endoscopic nasopharyngectomy for recurrent NPC.

His management philosophy centres on several principles:

• Multidisciplinary Tumour Board: Every NPC case is discussed in a multidisciplinary meeting involving head and neck surgeons, radiation oncologists, medical oncologists, radiologists, and pathologists. Treatment decisions are consensus-driven and evidence-based.

• Precise Pre-treatment Assessment: MRI, PET-CT, EBV DNA quantification, and audiological evaluation are completed before treatment begins. Dental assessment and nutritional optimisation are addressed proactively.

• Treatment Response Monitoring: Plasma EBV DNA levels are monitored during and after treatment. Post-treatment MRI at 12 weeks assesses response. Persistent or rising EBV DNA prompts early investigation for residual disease.

• Salvage Surgery Expertise: For patients with recurrent disease confined to the nasopharynx, Dr. Vidhyadharan offers endoscopic nasopharyngectomy. His MCh training in Head & Neck Surgery combined with skull base fellowship training provides the technical foundation for these complex procedures. With over 3000 head and neck surgeries performed, he brings extensive operative experience.

• Rehabilitation Integration: Speech therapy, swallowing rehabilitation, and hearing management are integrated into the care pathway from the outset, not introduced as afterthoughts.

What to Expect

During Initial Consultation

Your first appointment at THANC Hospital will include a detailed history and clinical examination, flexible nasoendoscopy, and review of any imaging or reports you bring. If NPC is suspected, a biopsy is performed during the same visit or scheduled within days. Dr. Vidhyadharan discusses the diagnostic findings, staging, and treatment plan in detail, ensuring you understand every step of the journey ahead.

During Chemoradiation

Chemoradiation treatment is delivered over 6-7 weeks, typically as an outpatient. You will receive daily radiation sessions (Monday through Friday) and weekly or three-weekly chemotherapy infusions. Common side effects during treatment include:

• Sore throat and difficulty swallowing (mucositis)
• Dry mouth (xerostomia)
• Taste changes
• Fatigue
• Nausea from chemotherapy
• Skin changes in the radiation field

The treatment team at THANC Hospital provides proactive supportive care -- nutritional support, pain management, and speech therapy -- to help you manage these side effects effectively.

If Surgery Is Needed

Patients requiring salvage endoscopic nasopharyngectomy can typically expect a hospital stay of 3-5 days. The surgery is performed entirely through the nose, leaving no external scars. Nasal packing is removed within 24-48 hours, and most patients resume oral intake within a day of surgery.

Recovery and Rehabilitation

Recovery after NPC treatment depends on the treatment modalities used:

• After chemoradiation: Most acute side effects (mucositis, fatigue) resolve within 4-6 weeks of completing treatment. Dry mouth may persist long-term but often improves gradually over 6-12 months. Hearing may be affected by both the disease and cisplatin chemotherapy, requiring audiological follow-up.

• After endoscopic nasopharyngectomy: Nasal crusting and mild nasal congestion are common for 2-4 weeks. Regular saline nasal irrigations are recommended. Endoscopic debridement of the surgical cavity is performed in the clinic at regular intervals during the healing phase.

• Long-term rehabilitation considerations: Patients may require speech therapy for velopharyngeal insufficiency, hearing aids for sensorineural hearing loss, thyroid hormone replacement (if the thyroid gland was within the radiation field), and ongoing dental care due to post-radiation xerostomia.

THANC Hospital's rehabilitation team works closely with each patient to address these needs, with structured follow-up protocols ensuring continuity of care.

Outcomes and Prognosis

NPC generally has favourable outcomes compared to many other head and neck cancers, particularly for non-keratinizing subtypes:

• Stage I: 5-year overall survival exceeds 90% with radiation alone.
• Stage II: 5-year survival rates of 80-85% with concurrent chemoradiation.
• Stage III: 5-year survival rates of 70-75% with combined modality treatment.
• Stage IVA-B: 5-year survival rates of 55-65%, improving with the addition of induction chemotherapy.

For recurrent NPC treated with endoscopic salvage nasopharyngectomy, 5-year local control rates of 60-75% have been reported in published series for appropriately selected patients (rT1-rT3 disease).

Key prognostic factors include stage at diagnosis, EBV DNA levels (both pre-treatment and post-treatment), WHO histological type, and treatment compliance. The single most impactful factor remains early detection -- patients diagnosed at Stage I-II have dramatically better outcomes than those presenting at Stage IV.

Why Choose Dr. Vidhyadharan

• MCh (Head & Neck Surgery) from Amrita Institute -- one of only a handful of surgeons in India with this super-speciality degree.
• Skull Base Surgery Training at Toronto General Hospital, Canada -- directly relevant to endoscopic nasopharyngectomy and complex nasopharyngeal surgery.
• Fellow, European Board of Otorhinolaryngology - Head & Neck Surgery (FEB-ORL HNS) -- the highest surgical qualification in Europe for this speciality.
• Fellow, Indian College of Robotic Surgeons (FICRS) -- trained in da Vinci robotic surgery for head and neck applications.
• 3000+ head and neck surgeries performed, including complex skull base and endoscopic procedures.
• Member of the World's First Endo-Robotic Surgery Team (2023).
• Training across 8 countries -- Australia, Singapore, Korea, Taiwan, Canada, and others -- bringing global best practices to patient care in Chennai.
• Co-Editor of "Comprehensive Management of Head and Neck Cancer" (Jaypee Brothers, 2021) and author of 40+ peer-reviewed publications.
• Multidisciplinary approach at THANC Hospital with integrated radiation oncology, medical oncology, speech therapy, and rehabilitation services under one roof.

Cost and Insurance

The cost of nasopharyngeal cancer treatment at THANC Hospital varies based on the stage of disease and treatment modalities required:

• Chemoradiation therapy: Costs depend on the radiation technique (IMRT), number of chemotherapy cycles, and supportive care needs. Treatment is often covered by health insurance when medically indicated.

• Endoscopic nasopharyngectomy (salvage surgery): Surgical costs vary with the complexity of the procedure, length of hospital stay, and whether reconstruction is required.

• Follow-up and surveillance: Includes periodic MRI, nasoendoscopy, EBV DNA monitoring, and audiological assessments.

Most health insurance plans in India -- including employer-provided group policies, government schemes (CGHS, ECHS, Ayushman Bharat), and private health insurance -- cover cancer treatment including NPC. THANC Hospital's billing team assists patients with insurance pre-authorisation, documentation, and claims processing. Transparent cost estimates are provided during the initial consultation based on your specific treatment plan.

For a personalised assessment and treatment plan, schedule a consultation with Dr. Vidhyadharan Sivakumar at THANC Hospital, Kilpauk, Chennai.

Phone: +91 73059 53378 Location: THANC Hospital, 747 Poonamallee High Road, Kilpauk, Chennai 600010 Book an Appointment

References

1. Lee, A.W.M., et al. "Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective." Journal of Clinical Oncology, 2015.
2. Zhang, Y., et al. "Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma." New England Journal of Medicine, 2019.
3. Chen, Y.P., et al. "Nasopharyngeal Carcinoma." The Lancet, 2019.
4. National Comprehensive Cancer Network (NCCN). "Head and Neck Cancers." NCCN Guidelines.
5. Ngan, R.K., et al. "Endoscopic Nasopharyngectomy for Locally Recurrent Nasopharyngeal Carcinoma." Head & Neck, 2014.
6. Indian Council of Medical Research (ICMR). National Cancer Registry Programme. Cancer Incidence Data for Northeastern India.
7. World Health Organization (WHO). "Classification of Head and Neck Tumours." 5th Edition, 2022.
8. Chan, J.Y.K., et al. "Endoscopic Salvage Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma: A Systematic Review." World Journal of Otorhinolaryngology - Head and Neck Surgery, 2021.